Follow-on protein products: scientific issues, developments and challenges.

Scientific and regulatory issues around approval of follow-on protein products, referred to as biosimilars in Europe, have been a topic of great interest and debate recently. The central issue is our limited understanding of how the different quality attributes of a product have an impact on its safety and efficacy. Crucial gaps in our knowledge include a lack of standardization in the way in which data are collected, analyzed and reported, and limitations in the ability of non-clinical tools for predicting clinical safety and efficacy. Complexity of protein products with respect to the numerous quality attributes and complexity of the biotechnology processes and the raw materials add to the challenges. In this paper, recommendations are presented to help at least partially alleviate these challenges.

[1]  A. Rathore,et al.  Application of Multivariate Data Analysis for Identification and Successful Resolution of a Root Cause for a Bioprocessing Application , 2008, Biotechnology progress.

[2]  Charles F. Goochee,et al.  Environmental Effects on Protein Glycosylation , 1990, Bio/Technology.

[3]  Patrick G. Swann,et al.  Considerations for the development of therapeutic monoclonal antibodies. , 2008, Current opinion in immunology.

[4]  B. Sharma.  Immunogenicity of therapeutic proteins. Part 2: impact of container closures. , 2007, Biotechnology advances.

[5]  J. Egrie,et al.  Development and characterization of novel erythropoiesis stimulating protein (NESP) , 2001, British Journal of Cancer.

[6]  B. Helk,et al.  Chip-based gel electrophoresis method for the quantification of half-antibody species in IgG4 and their by- and degradation products. , 2004, Analytical biochemistry.

[7]  Leonard G Presta,et al.  Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. , 2006, International immunology.

[8]  Gopi Shankar,et al.  A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs , 2007, Nature Biotechnology.

[9]  Steven Kozlowski,et al.  Current and future issues in the manufacturing and development of monoclonal antibodies. , 2006, Advanced drug delivery reviews.

[10]  B. Sharma.  Immunogenicity of therapeutic proteins. Part 1: impact of product handling. , 2007, Biotechnology advances.

[11]  Xiangyang Wang,et al.  Case Study on Definition of Process Design Space for a Microbial Fermentation Step , 2008 .

[12]  Fiona Adair,et al.  The immunogenicity of therapeutic proteins , 2002 .

[13]  J. Woodcock,et al.  The Prospects for “Personalized Medicine” in Drug Development and Drug Therapy , 2007, Clinical pharmacology and therapeutics.

[14]  Leonard Moise,et al.  Prediction of immunogenicity for therapeutic proteins: state of the art. , 2007, Current opinion in drug discovery & development.

[15]  F. Locatelli,et al.  Comparative testing and pharmacovigilance of biosimilars. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  Huub Schellekens,et al.  Factors influencing the immunogenicity of therapeutic proteins. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  Steven Kozlowski,et al.  The FDA's assessment of follow-on protein products: a historical perspective , 2007, Nature Reviews Drug Discovery.

[18]  Xiangyang Wang,et al.  Defining Process Design Space for Biotech Products: Case Study of Pichia pastoris Fermentation , 2008, Biotechnology progress.

[19]  Gary Walsh,et al.  Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.

[20]  H. Schellekens.  Recombinant human erythropoietins, biosimilars and immunogenicity. , 2008, Journal of nephrology.

[21]  Marian Kelley,et al.  Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. , 2007, Journal of immunological methods.

[22]  Huub Schellekens,et al.  Biosimilar therapeutics—what do we need to consider? , 2009, NDT plus.

[23]  A. Rathore,et al.  Quality by design for biopharmaceuticals , 2009, Nature Biotechnology.

[24]  Anurag S Rathore,et al.  Application of Multivariate Analysis toward Biotech Processes: Case Study of a Cell‐Culture Unit Operation , 2007, Biotechnology progress.

[25]  C Thomas Caskey,et al.  The drug development crisis: efficiency and safety. , 2007, Annual review of medicine.

[26]  James L. Vesper.  Assessing and managing risks in a GMP environment , 2005 .

[27]  Maureen Lanan.  QbD for Raw Materials , 2008 .

[28]  Kripa Ram,et al.  Using a Risk Assessment Process to Determine Criticality of Product Quality Attributes , 2008 .

[29]  Anurag S Rathore,et al.  Roadmap for implementation of quality by design (QbD) for biotechnology products. , 2009, Trends in biotechnology.

[30]  G. A. Lazar,et al.  Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. Schneider,et al.  Toward biosimilar monoclonal antibodies , 2008, Nature Biotechnology.

[32]  Huub Schellekens,et al.  Immunogenicity of therapeutic proteins: clinical implications and future prospects. , 2002, Clinical therapeutics.

[33]  T. Arakawa,et al.  Protein isolated from biopharmaceutical formulations cannot be used for comparative studies: Follow-up to "a case study using Epoetin Alfa from Epogen and EPREX". , 2007, Journal of pharmaceutical sciences.

[34]  Anthony Mire-Sluis,et al.  Characterizing biological products and assessing comparability following manufacturing changes , 2004, Nature Biotechnology.

[35]  T. Boone,et al.  Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.

[36]  Anurag S Rathore,et al.  Case study and application of process analytical technology (PAT) towards bioprocessing: Use of on‐line high‐performance liquid chromatography (HPLC) for making real‐time pooling decisions for process chromatography , 2008, Biotechnology and bioengineering.

[37]  Robert A. Lionberger,et al.  FDA Critical Path Initiatives: Opportunities for Generic Drug Development , 2008, The AAPS Journal.

[38]  Jill Crouse-Zeineddini,et al.  Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. , 2009, Journal of pharmaceutical sciences.

[39]  Basant Sharma,et al.  Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. , 2007, Biotechnology advances.

[40]  H. Schellekens.  Immunogenicity of therapeutic proteins. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  Michael Butler,et al.  Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals , 2005, Applied Microbiology and Biotechnology.

[42]  Anurag S. Rathore,et al.  Filter Clogging Issues in Sterile Filtration , 2008 .

[43]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[44]  Shigeru Iida,et al.  Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.

[45]  Erwin Freund,et al.  Protein formulation and fill-finish operations. , 2002, Biotechnology annual review.

[46]  C. Zoccali,et al.  Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  N. Casadevall,et al.  The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. , 2005, Kidney international.

[48]  M. Pavlovic,et al.  Similar Biological Medicinal Products Containing Recombinant Human Growth Hormone: European Regulation , 2007, Hormone Research in Paediatrics.

[49]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[50]  Janet Woodcock,et al.  The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.

[51]  Steven Kozlowski,et al.  Considerations for Biotechnology Product Quality by Design , 2008 .

[52]  R. Senger,et al.  Effect of Shear Stress on Intrinsic CHO Culture State and Glycosylation of Recombinant Tissue‐Type Plasminogen Activator Protein , 2008, Biotechnology progress.

[53]  Difei Qiu,et al.  C‐terminal lysine variants in fully human monoclonal antibodies: Investigation of test methods and possible causes , 2008, Biotechnology and bioengineering.

[54]  Pauline M Rudd,et al.  The impact of glycosylation on the biological function and structure of human immunoglobulins. , 2007, Annual review of immunology.

[55]  Gerd R Kleemann,et al.  Optimization of a reversed-phase high-performance liquid chromatography/mass spectrometry method for characterizing recombinant antibody heterogeneity and stability. , 2006, Journal of chromatography. A.

[56]  Harold S. Baseman,et al.  PDA survey of quality risk management practices in the pharmaceutical, devices, & biotechnology industries. , 2008, PDA journal of pharmaceutical science and technology.

[57]  Anne S De Groot,et al.  Immunogenicity of protein therapeutics. , 2007, Trends in immunology.